When Regeneron (REGN) was a development stage firm, it spent a
substantial time in developing and validating a solid
scientific, technological and industrial infrastructure. At its
inception, Regeneron’s vision was to provide a self-sufficient
capability for discovering and developing far-reaching
breakthrough products. Its strategy for its therapeutic
discovery has been to establish a solid foundation that enables
it to build its pipeline product through in house genomic
technology for understand functional gene expression. Its drug
design strategy focused on creating a novel approach, which
would enable controlling signaling proteins, whose excesses
cause cell deregulation. The strategy focused also on designing
human monoclonal antibodies that are far-reaching, time
consuming and impacting. Until the time these technologies were
put in place and was validated, REGN served as a vehicle for
daily trading. Both positive and negative players benefited from
the yo-yoing of the stock. Stock investors and analyst